Abstract Autosomal, dominantly inherited, non-chromaffin paragangliomas are tumors of the head and neck region occurring with a frequency of 1:30 000. Genomic imprinting probably influences the expression of the disorder, because tumor development is limited to individuals who have inherited the trait from their father. By linkage analysis and haplotyping of a single large family in which the pattern of inheritance is consistent with genomic imprinting, we have mapped the gene to a 5 cM region of chromosome llq13.1 between DllS956 and PYGM. A maximum lod score of 7.62 at @ = 0.0 was obtained for D11 $480. This interval does not overlap with a recently assigned locus for glomus tumors in other families: l lq22.3-q23.3. Furthermore, analysis of a second family showing the imprinting phenomenon resulted in the exclusion of the 5 cM area as the location of the disease gene, whereas an indication for linkage was obtained (Z = +2.65) with markers from the distal locus. These observations argue for the presence of two distinct imprinted genes for glomus tumors on 11 q. A model for tumor initiation and progression is presented based on all available information.
Introduction
Non-chromaffin paragangliomas, also referred to as glomus tumors or chemodectomas, are slow-growing tumors usually located at the head and neck region of the body at the crossing of parasympathetic nerves and large vessels. They occur among Caucasians with a frequency of about
Materials and methods

Ascertainment of families and DNA isolation
The families studied here have been described before: Family 1 (van Baars et al. 1982; Mariman et al. 1993) , Family 2 (Bleker and Wereldsma 1986) . The patients were diagnosed by standard clinical examinations and, if necessary as in the case of offspring of female carriers, by whole body magnetic resonance imaging (MRI). During the past 12 years, several new cases have been included in Family 1. Family 2 has been extended by our group since 1986 with an extra branch comprising two affected sisters and their father (individual III. l in Fig. 3 ) who, by MR1 examination, was shown to be clinically unaffected, probably because of genomic imprinting. Cytogenetic analysis of blood cells from patients of Family 1, including fluorescence in situ hybridization with various cosmid clones, revealed no gross rearrangements of 1 lq or any other chromosome. Venous blood was sampled from relevant family members and genomic DNA was isolated as described by Miller et al. (1988) . Fig. 1 Location of highly polymorphic markers in the pericentromeric region of chromosome 11. The relative order and genetic distances are based on data obtained from the Genome Data Base. The position of two markers, CNTF and D11S480, with respect to D11S956 is less certain, because CNTF was mapped by in situ hybridization (Giovannini et al. 1993) , whereas D11S480 has only been genetically localized with respect to PYGM (Fujimori et al. 1992 
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Analysis of genetic markers
Highly polymorphic markers were selected from the pericentromeric region of chromosome 11. Their order and estimated genetic distances are shown in Fig. 1 . Markers were also selected from the region between STMY and CD3D (Table 1) , to which a gene for glomus tumors has been assigned by others (Heutink et al. 1994 ). All markers (Table 1) were analyzed by polymerase chain reaction amplification of genomic DNA under the conditions described by Weber and May (1989) and by using locusspecific primers as given in the Genome Data Base. In the reaction mixture, 32p-dCTP was included to label the amplification products. Amplification was performed in a 96-well thermal cycler (MJ Research, Watertown) with Super Taq DNA polymerase (HT Biotechnology, Cambridge). Subsequently, the DNA fragments were loaded on standard 6.6% denaturing polyacrylamide gels and separated by electrophoresis for 3 h at 60W. The gels were then dried and exposed to Kodak X-ray film to visualize the individual allelic bands.
Linkage analysis
Lod scores were calculated with the MLINK and LINKMAP options of the program LINKAGE version 5.10 (Lathrop et al. 1985) . A frequency of 1:50000 was assumed for the glomus tumor gene. For children from male carriers, five liability classes were defined to account for age-dependent tumor development (van Baars et al. 1982 ): 1.0 (>50 years of age), 0.9 (40-50 years), 0.6 (30-40 years), 0.3 (20-30 years), and 0.1 (< 20 years). Multipoint linkage analysis of Family 2 (Fig. 3 ) was performed with D11S956 and PYGM, which are separated by 5cM (Litt et al. 1993) , and with DllS897 and DllS490 at a distance of 14cM (CllM19, CllM48 of GDB). Genomic imprinting was assumed for the second and third generation, and was incorporated into the linkage calculations by a separate liability class with a penetrance of 0.0 for children of female gene cartiers (Heutink et al. 1992) . For most marker loci, linkage analyses were based on the reported allele frequencies, except for CNTF and D 11 $480. For these markers, allele frequencies were determined by the analysis of 50 unrelated persons from the Dutch population. 
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Results
Two-point linkage analysis in Family 1
Part of Family 1 has previously been studied by linkage analysis with markers distributed along chromosome 11 q (Mariman et al. 1993 ). An indication for linkage was obtained in pedigree A between the disorder and markers FGF3 (formerly INT2, 11q13.3) and D11S527 (11q13.5), whereas recombination had been observed with the locus for TYR (l lq14-q21). Furthermore, different FGF3 alleles were seen to co-segregate with the disorder in Pedigrees A and B, suggesting that the gene for glomus tumors is located proximal to FGF3. To increase the informativity of Family 1, a considerable number of family (Fig. 2) . Highly polymorphic markers were selected from the pericentromeric region of chromosome 11 (Fig. 1 ) and linkage analysis was performed with a part of Family 1 comprising Pedigrees A ( Fig. 2A) and B (Fig. 2B) . As can be seen in Table 1 , positive lod scores were obtained with most of the markers. For CNTF and DllS480, maximum lod scores of 5.23 and 7.62 were obtained at | = 0.0. For these two markers, the same allele was seen to co-segregate with the disorder throughout the family, whereas for all other tested markers, different alleles appeared to co-segregate in Pedigrees A and B, respectively, suggesting recombination(s) between these markers and the disease gene. In addition, four markers from the distal region, defined by Heutink et al. (1994) as the location of a gene for glomus tumors, were used for two-point linkage analysis (Table 1) . Negative lod scores were obtained with all of these markers (Table 1) , thus substantiating our previous conclusion that, in Family 1, the location of the gene is more proximal.
Haplotype analysis of Family 1
Haplotypes were constructed from the alleles of six marker loci used for linkage analysis. In pedigree A ( Fig.  2A) , a common haplotype segregates with the disorder in the offspring of individual A-IV.3. When the affected female A-V. 1 is included in the analysis, the common haplotype is limited to the lower three markers. Therefore, the responsibe gene is located distal to D11S956. In pedigree B (Fig. 2B) , a common haplotype was constructed for the affected persons only, minimizing the number of recombination events (Thompson 1987) . A comparison of this haplotype with that of female A-V. 1 ( Fig. 2A) shows that they have only that part defined by the upper four markers in common. From these data, we conclude that the gene for glomus tumors in Family 1 is located at llq13.1 between DllS956 and PYGM within a region of 5 cM. Marker D11 $480, which lies at a distance 4 cM proximal from PYGM (Fujimori et al. 1992) , showed no recombination with the disorder. Genotyping the available persons of Pedigree C ( Fig.2C ; C-VII.1 and her parents) established that the patient inherited the same haplotype as patients of Pedigree B; this does not allow further fine-mapping of the underlying gene. Evidence for genetic heterogeneity
Another family with inherited glomus tumors, Family 2 (Fig. 3) , was investigated similarly. The pattern of inheritance in this family is consistent with genomic imprinting. Affected persons have received the predisposing gene from their father, whereas male Ill.l, who has inherited the genetic defect from his mother, shows no signs of the disorder at the age of 65. Moreover, no signs of tumor development were noticed by clinical examination or by MRI in the living obligate carriers of the second generation, despite their longevity (>79 years). This suggests that the genetic defect was inherited from the great-grandmother 1.2. Multipoint linkage analysis was performed with the flanking markers DI 1S956 and PYGM. As can be seen in Fig. 4 , the interval between DllS956 and PYGM is excluded as the location of the gene for g|omus tumors in this family (Z < -2). The maximum multipoint lod score was Z = -3.47. When markers from the region l lq22.3~q23.3 were used for linkage analysis, positive lod scores were obtained. Multipoint linkage analysis was performed with DllS897 and DllS490 to optimize the informativity and this yielded a maximum lod score of Z = +2.65 at DllS490. Together, these findings argue for the involvement of two separate genes, both located on chromosome 1 lq, and both predisposing for the development of glomus tumors.
Discussion
The present study strongly supports the existence of genetic heterogeneity in the predisposition for glomus tumor development, with two genes being located on chromosome 1 lq. The data reported here show that one of these genes is located close to the centromere at llql3.1, whereas the other gene has been mapped to l lq22.3-q23.3 (Heutink et al. 1994) . The pericentromeric region of chromosome l l contains at least three genes coding for factors, (neurotrophins) that are able to regulate in vitro the growth and differentiation of specific neurons; these factors include brain-derived neurotrophic factor (BDNF, llpl3), midkine (MDK, NEGF2, llpll.2), and ciliary neurotrophic factor (CNTF, l lq12). They may also be able to influence the growth of paraganglionic cells, and their genes can be regarded as candidates for the present disorder. The gene for CNTF, for which no recombination was observed in Family 1, has been mapped to l lq12 by in situ hybridization (Giovannini et al. 1993) . However, regarding the restricted resolution of this procedure, band 1 lq13.1 is not excluded as the location of the CNTF gene . Therefore, we have tested the coding region of this gene by single-strand conformation analysis for the presence of mutations in patients with glomus tumors. So far, no mutations have been detected. Previously, linkage calculations have provided evidence for genomic imprinting of the distally located gene (Heutink et al. 1992) . The same gene probably underlies the disorder in our present Family 2, where the pattern of inheritance is consistent with genomic imprinting. In Family 1, all 30 patients have inherited the trait from their father, whereas the obligate carrier C-VI.2 (Fig. 2C) , who has a maternally inherited genetic defect, has no clinical signs at the age of 65. Apparently, the proximal gene is also subject to genomic imprinting.
What is the role of genomic imprinting in tumor development and how does it relate to the increased risk for tumors in the offspring of male carriers? Patients often develop more than one tumor affecting different glomus bodies. These tumors apparently originate from different paraganglionic cells, suggesting that one or both of the predisposing genes on 11 q code for tumor-suppressor proteins. Assuming that both genes code for functionally equivalent tumor suppressors, the Knudson hypothesis (Knudson 1986 ) would predict that both copies of the two genes have to be turned off before glomus tumors can develop (Fig. 5) . In this respect, genomic imprinting would account for the silencing of the two maternal copies, A In the normal situation, the maternal gene copies are inactive because of genomic imprinting (cross-hatched boxes), whereas the paternal copies produce a growth suppressing protein (S). The same is true in the case of a maternally inherited mutation in one of the genes. B When a mutation is inherited paternally, only one gene copy produces the suppressor protein.
As soon as a somatic mutation turns off the remaining copy, the cell is released from growth suppression and will start to divide. Upon loss of imprinting of one or both of the maternal gene copies, tumor progression would require their transcriptional inactivation by mutation or deletion whereas a paternally inherited mutation in one of the genes would represent the third hit. A single somatic mutation in the remaining active paternal copy would subsequently suffice to initiate tumor growth (Fig. 5B) . Maternally inherited mutations would not (or only very rarely) give rise to tumor development because it would require the inactivation of the two paternally transcribed gene copies in a single cell (Fig. 5A) . Recently, allelic imbalance was observed in glomus tumors for markers on 11 q with (partial) loss of maternal alleles ). This phenomenon can be neatly explained by our model, assuming that, as observed for imprinted genes in other tumors (Ogawa et al. 1993; Rainier et al. 1993; Gurp et al. 1994) , the imprinted copies of the glomus tumor genes can become transcriptionally active. In this case, tumor progression would require additional hits, e.g., the somatic loss of the maternal chromosome (Fig.5B) . Although the proposed model, based on imprinting, is able to account for the relative risk for tumor development in disease gene carriers, and for the molecular events observed in tumor cells, stronger evidence has to await the isolation of both glomus tumor genes and the elucidation of their transcriptional regulation.
